Inhibition of MAPK activation by MEK inhibitors was successfully used in various in vivo and in vitro research models of RASopathy pathophenotype related to prenatal lethality, craniofacial abnormalities, cardiac defects, skeletal myopathy, and enhanced osteoclastogenesis22,63,64. This evidence concerns the gene MAP2K7 and RASopathy.